Dr. Moran, Improving Personalization and Confidence in Prostate Cancer Treatment

Dr. Brian J. Moran, Medical Director for the Chicago Prostate Cancer Center, stresses the importance of customizing each and every patient’s cancer treatment. “This disease is a spectrum disease,” says Moran.

Brachytherapy: An Innovative Disruptor

Dr. Brian Moran, Medical Director for the Chicago Prostate Center, discusses the value of low-dose rate brachytherapy and its disruptive innovation in the cancer treatment field at ABS 2018.

IsoRay Announces FDA Clearance of GammaTile™ Therapy for the Treatment of Recurrent Brain Neoplasms

GammaTile Therapy is the Next Step in the Expansion of Cesium to Additional Markets RICHLAND, Wash., July 09, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...

ABS 2018 Insights: Science, Improving Your Practice, Social Time & Thanks

With the 2018 edition of the American Brachytherapy Annual Meeting in the books, it is fitting to take a few minutes and highlight our top ABS 2018 Insights. The clinical experience with Cesium-131 continues to build: Dr. Manuj Agarwal of the University of Maryland...

Prostate Cancer News Today: “Prostate Cancer Patients Treated with Radioactive Seeds Retain Urinary, Bowel Quality”

“Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a recent study.” The study, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was...

Recent News

Dr. Brian J. Moran, Awareness in Action and Sky High Referral Rates

“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.

Cs-131 is a favorable isotope for use across a wide range of tumors and its dose distribution properties facilitate easy calculation and use in the clinic. Dr. Voichita Bar-Ad

Thomas Jefferson University Hospital

Find A Cesium Pioneer Near You

Doctors going above and beyond against the fight with cancer.
Learn More

All News

Dr. Brian J. Moran, Awareness in Action and Sky High Referral Rates

“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.

Will AUA 2018 be the catalyst for a resurgence in brachytherapy?

Year after year, the Isoray team attends the American Urological Association annual meeting - it is undoubtedly one of the events we look forward to most. During last year’s AUA meeting, there was limited data presented on the use of targeted (focal) therapy. In...